Overview

Calista Therapeutics was founded in 2012 by peptide therapeutic pioneer and biotech entrepreneur, Andrew Mallon, building upon years of research and business experience in discovering and developing peptide drugs. Calista scientists are today developing these promising leads to create more effective and safe medicines for the treatment of cystic fibrosis, dry eye, radiation damage, neuroprotection and other indications. Our expertise in the pharmacology and development of peptide drugs that interact with key cellular disease targets.